Tags: Drug.

SGN-CD19A is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF) a cytotoxic agent.The drug is currently in phase I clinical trials.

Loading...

This page contains content from the copyrighted Wikipedia article "SGN-CD19A"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.